Coronary Heart Disease (CHD)
Conditions
Brief summary
Coronary heart disease (CHD) stands as a foremost contributor to global mortality, characterized by complex pathogenesis that renders conventional one-size-fits-all preventive strategies inefficient. Therefore, the investigators designed a prospective, multi-center cohort study among patients hospitalized due to either confirmed or suspected CHD, which aimed to establish a holographic data set for the diagnosis and treatment of CHD and explore the impact of critical therapeutic strategies in the real world on the clinical outcomes of CHD patients, providing evidence to optimize the management pathway.
Detailed description
Coronary heart disease (CHD) stands as a foremost contributor to global mortality. Despite the increasing investment in the prevention of risk factors and the popularization of percutaneous coronary intervention (PCI), the age-standardized incidence and mortality of CHD continue to increase. CHD is characterized by complex pathogenesis, rendering conventional one-size-fits-all preventive strategies inefficient. Currently, there is a need to address two critical challenges. The first centers on early detection, precise risk stratification, and personalized intervention strategies for high-risk CHD patients, with a focus on the exploration of inflammation-driven risks, lesion-based risk stratification, and tailored anti-thrombotic therapies. The second challenge lies in the transformation of clinical risk assessment and decision-making processes into a precise level through the utilization of big data mining techniques. Therefore, the investigators designed a prospective, multi-center cohort study among patients hospitalized due to either confirmed or suspected CHD, which aimed to establish a holographic data set for the diagnosis and treatment of CHD and explore the impact of critical therapeutic strategies in the real world on the clinical outcomes of CHD patients, providing evidence to optimize the management pathway.
Interventions
None listed
Sponsors
Shenyang Northern Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old * Hospitalization due to either confirmed or suspected CHD combined with one of the following features: previous PCI or CABG; previous myocardial infarction; previous coronary angiography revealing ≥ 50% stenosis in major coronary vessels; presentation with chest pain and pre-test probability of CHD \> 65%; laboratory tests revealing objective evidence of myocardial ischemia; coronary CT angiography (CTA) showed ≥ 30% stenosis in major coronary vessels * Subjects undergoing at least one coronary imaging and one functional examination. Imaging examinations include coronary CTA, intravascular ultrasound (IVUS), or optical coherence tomography (OCT). Functional examination include fraction flow reservation (FFR), CT-FFR or quantitative flow ratio (QFR). * Written informed consent provided.
Exclusion criteria
* History of mental illness, drug or alcohol abuse, or being unable to cooperate with follow-up visits for any reason; * Life expectancy \<1 year * Pregnant or plan to be pregnant within 1 year * Subjects participating in any other clinical trial * Other conditions deemed unsuitable for inclusion by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ischemic events | During 12-month follow up | defined as the composite of cardiac death, myocardial infarction, or stroke |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major adverse cardiovascular and cerebrovascular events (MACCE) | During 1/2/3/4/5-year follow up | defined as a composite of all-cause death, myocardial infarction, ischemic stroke and target-vessel revascularization |
| Cardiac death | During 1/2/3/4/5-year follow up | — |
| Stent thrombosis | During 1/2/3/4/5-year follow up | — |
| Major bleeding events | During 1/2/3/4/5-year follow up | defined as BARC types 3 or 5 bleeding events |
| Clinical relevant bleeding events | During 1/2/3/4/5-year follow up | defined as BARC type 2-5 bleeding events |
Countries
China
Contacts
Primary ContactYi Li, MD
Backup ContactYaling Han, MD
Outcome results
None listed